In triple-negative breast cancer (TNBC), SV2A has been identified as a biomarker that predicts differential responses to chemotherapy in patient-derived xenografts (Petrosyan et al., 2023). The gene discussed is SV2A; the disease is triple-negative breast carcinoma.